Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glioblastoma, Glioma Clear all
Terminated Phase 2 Interventional Results available

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

NCT03347617
View directory record Official record
Conditions
Glioblastoma
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

NCT01547546
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
GDC-0084
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 9, 2026, 2:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

NCT03452579
View directory record Official record
Conditions
Glioblastoma
Interventions
Nivolumab, Standard Dose Bevacizumab, Low Dose Bevacizumab
Drug
Lead sponsor
David Peereboom
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma

NCT02067156
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study

NCT01865162
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ketogenic diet
Other
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 9, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NCT03911388
View directory record Official record
Conditions
Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms, Astrocytoma, Astrocytoma, Cerebellar, Neuroectodermal Tumors, Neuroectodermal Tumors, Primitive, Cerebellar PNET, Childhood, Cerebellar Neoplasms, Cerebellar Neoplasms, Primary, Cerebellar Neoplasm, Malignant, Cerebellar Neoplasm Malignant Primary, Neoplasm Metastases, Neoplasm Malignant, Neoplasms, Neuroepithelial, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Central Nervous System Neoplasms, Primary, Central Nervous System Neoplasms, Malignant, Nervous System Neoplasms, Neoplasms by Site, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Medulloblastoma Recurrent, HSV, Virus, Pediatric Brain Tumor, Nervous System Cancer, Primitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
G207
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
36 Months to 22 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA

NCT01833273
View directory record Official record
Conditions
Glioblastoma Multiform (Grade IV Astrocytoma)
Interventions
PolyMVA
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 79 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Not applicable Interventional Results available

Mathematical Model-Adapted Radiation In Glioblastoma

NCT03557372
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Mathematical Model-Adapted Radiation Fractionation Schedule
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

NCT04013672
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Pembrolizumab, SurVaxM, Sargramostim, Montanide ISA 51
Drug
Lead sponsor
David Peereboom
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas

NCT00612339
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Avastin and Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer

NCT00003022
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
iodine I 131 monoclonal antibody 3F8
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

NCT02490930
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma
Interventions
Fingolimod
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 9, 2026, 2:41 PM EDT
Active, not recruiting Phase 2 Interventional

Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

NCT04195139
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nivolumab, Temozolomide
Drug
Lead sponsor
University of Sydney
Other
Eligibility
65 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

NCT01934361
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
buparlisib, carboplatin, lomustine, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 9, 2026, 2:41 PM EDT
Active, not recruiting Phase 1 Interventional

CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

NCT05168423
View directory record Official record
Conditions
Glioblastoma
Interventions
CART-EGFR-IL13Ra2 Cells
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma

NCT00792012
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Hypofractionated Intensity-Modulated Radiation Therapy, Temozolomide
Radiation · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

NCT04388475
View directory record Official record
Conditions
Recurrent Malignant Glioma, Brain Glioblastoma
Interventions
OKN-007, Temozolomide (TMZ)
Drug
Lead sponsor
Oblato, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

NCT00004212
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, exatecan mesylate
Biological · Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5

NCT00743353
View directory record Official record
Conditions
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, High Grade Gliomas
Interventions
F-18 RGD-K5
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Days and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lenalidomide, Bevacizumab, Sorafenib, Temsirolimus, Oxaliplatin, Leucovorin, 5-fluorouracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

NCT03632135
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
ChemoID assay, Chemotherapy
Diagnostic Test · Drug
Lead sponsor
Cordgenics, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
13
States / cities
Los Angeles, California • New Orleans, Louisiana • Scarborough, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional

MET-PET for Newly Diagnosed Glioblastoma

NCT01867593
View directory record Official record
Conditions
Glioblastoma
Interventions
C-11 methionine PET
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 9, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

NCT06146738
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult
Interventions
Palliative Care, Tumor biopsy, Tumor resection
Behavioral · Procedure
Lead sponsor
Jasper Gerritsen
Other
Eligibility
18 Years to 90 Years
Enrollment
1,015 participants
Timeline
2023 – 2029
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 9, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

NCT00066248
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cyproheptadine hydrochloride, megestrol acetate
Drug
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
40
States / cities
Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 9, 2026, 2:41 PM EDT